Overview

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the progression free survival (PFS), overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), duration of response (DoR), quality of life, safety and tolerability of tivozanib in combination with mFOLFOX6 and bevacizumab in combination with mFOLFOX6.

Phase:

Phase 2

Details

Lead Sponsor:

AVEO Pharmaceuticals, Inc.

Treatments:

Bevacizumab